ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1677

Effects of Biological-DMARDs on the Serum Low-density Lipoprotein (LDL) / High-density Lipoprotein (HDL) – Cholesterol Ratio in Patients with Rheumatoid Arthritis
Abstract Number: 1678

Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial
Abstract Number: 1679

Effectiveness and Safety of Tocilizumab SC Every 10 Days in Patients with Rheumatoid Arthritis Who Previously Used Tocilizumab EV During the COVID 19 Pandemic at the Hospital Docente Padre Billini, Dominican Republic
Abstract Number: 1680

Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials
Abstract Number: 1681

ATI-450, an Investigational MK2 Inhibitor, Is Well Tolerated and Demonstrated Clinical Activity in Patients with Mod/severe RA: A 12-week Phase 2a, Randomized, Investigator/patient-blind Study Investigating the Safety, Tolerability, PK and PD of ATI-450 + MTX vs PBO + MTX in MTX IR Patients
Abstract Number: 1682

Impact of Type, Dose and Duration of Oral Polyunsaturated Fatty Acid Supplementation on Disease Activity in Inflammatory Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
Abstract Number: 1683

Abatacept in Usual and in Non-Specific Interstitial Pneumonia Associated to Rheumatoid Arthritis. National Multicenter Study of 190 Patients
Abstract Number: 1684

Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Abstract Number: 1685

Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – Placebo and Active Controlled Study
Abstract Number: 1686

Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by TNF-α Inhibitor Therapy
Abstract Number: 1687

Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial
Abstract Number: 1688

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 9.3 Years: An Updated Integrated Safety Analysis
Abstract Number: 1689

Safety, Tolerability, Pharmacokinetics, Receptor Occupancy, and Suppression of T-cell-Dependent Antibody Response in a Phase 1 Study with KPL-404, an anti-CD40 Monoclonal Antibody
Abstract Number: 1690

Safety and Efficacy of Long-term Sarilumab Treatment in Patients with Active Rheumatoid Arthritis: EXTEND and MONARCH Open Label Extension Studies
Abstract Number: 1691

Long-Term Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].